Bridging the gap between translational research and clinical application

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 134-137

  Miller, William R ^a,b   Larionov, Alexey A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; LETROZOLE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER SURGERY; CELL CYCLE PROGRESSION; CELL HETEROGENEITY; CLINICAL PRACTICE; CONSERVATIVE TREATMENT; DISEASE COURSE; DRUG MECHANISM; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME; ADJUVANT THERAPY; BREAST TUMOR; CLINICAL MEDICINE; FEMALE; HUMAN; METHODOLOGY; PERSONALIZED MEDICINE; PREDICTIVE VALUE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL MEDICINE; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84855177370     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr020     Document Type: Article

References (23)

1. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18(12):1927-1934.
2. Murray J, Miller WR, Dixon JM. Neoadjuvant endocrine therapy models. Methods Mol Med. 2006;120:489-502.
3. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380-1388.
4. Dixon JM. The scientific value of preoperative studies and how they can be used. Breast Cancer Res Treat. 2004;87(suppl 1):S19-S26.
5. Miller WR, Larionov A, Renshaw L, et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol. 2009;27(9):1382-1387.
6. Klauber-DeMore N, Van Zee KJ, Linkov I, Borgen PI, Gerald WL. Biological behavior of human breast cancer micrometastases. Clin Cancer Res. 2001;7(8):2434-2439.
7. Pestrin M, Bessi S, Galardi F, et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat. 2009;118(3):523-530.
8. Forouhi P, Walsh JS, Anderson TJ, Chetty U. Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment. Br J Surg. 1994;81(2):223-225.
9. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460-469.
10. Miller WR, Dixon JM, Cameron DA, Anderson TJ. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol. 2001;79(1-5):103-107.
11. Sasano H, Suzuki T, Moriya T. Pathology of breast cancer following neoadjuvant therapy. In: Miller WR, Ingle JN, eds. Endocrine Therapy in Breast Cancer. New York, NY: Marcel Dekker; 2002:213-222.
12. Miller WR, Dixon JM, MacFarlane L, Cameron D, Anderson TJ. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer. 2003;39(4):462-468.
13. Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer. 2006;94(7):1051-1056.
14. Tao Y, Klause A, Vickers A, Bae K, Ellis M. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. J. Steroid Biochem Mol Biol. 2005;95(1-5):91-95.
15. Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005;11(2 Pt 2):S951-S958.
16. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19(18):3808-3816.
17. Miller WR, Larionov AA, Renshaw L, et al. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics. 2007;17(10):813-826.
18. Miller WR, Larionov A, Anderson TJ, Evans DB, Dixon JM. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole [published online ahead of print August 10, 2010]. Pharmacogenomics J. 2010. doi:10.1038/tpj.2010.67.
19. Dixon JM. Neoadjuvant therapy: surgical perspectives. In: Miller WR, Ingle JN, eds. Endocrine Therapy in Breast Cancer.NY: Marcel Dekker; 2002:197-212.
20. Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park). 2009;23(2):133-142.
21. Iqbal S, Anderson TJ, Marson LP, Prescott RJ, Dixon JM, Miller WR. MIB-1 assessments in breast cancers. Breast. 2002;11(3):252-256.
22. Miller WR, Larionov A. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Res. 2010;12(4):R52.
23. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008;26(5):721-728.